Defective RNA polymerase III is negatively regulated by the SUMO-ubiquitin-Cdc48 pathway

Zheng Wang, Catherine Wu, Aaron Aslanian, John R. Yates, Tony Hunter

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Transcription by RNA polymerase III (Pol III) is an essential cellular process, and mutations in Pol III can cause neurodegenerative disease in humans. However, in contrast to Pol II transcription, which has been extensively studied, the knowledge of how Pol III is regulated is very limited. We report here that in budding yeast, Saccharomyces cerevisiae, Pol III is negatively regulated by the Small Ubiquitin-like MOdifier (SUMO), an essential post-translational modification pathway. Besides sumoylation, Pol III is also targeted by ubiquitylation and the Cdc48/p97 segregase; these three processes likely act in a sequential manner and eventually lead to proteasomal degradation of Pol III subunits, thereby repressing Pol III transcription. This study not only uncovered a regulatory mechanism for Pol III, but also suggests that the SUMO and ubiquitin modification pathways and the Cdc48/p97 segregase can be potential therapeutic targets for Pol III-related human diseases.

Original languageEnglish (US)
Article numbere35447
JournaleLife
Volume7
DOIs
StatePublished - Sep 2018
Externally publishedYes

Fingerprint

RNA Polymerase III
Transcription
Ubiquitin
Yeast
Neurodegenerative diseases
Sumoylation
Saccharomycetales
Ubiquitination
Post Translational Protein Processing
Neurodegenerative Diseases
Saccharomyces cerevisiae
Degradation
Mutation
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Defective RNA polymerase III is negatively regulated by the SUMO-ubiquitin-Cdc48 pathway. / Wang, Zheng; Wu, Catherine; Aslanian, Aaron; Yates, John R.; Hunter, Tony.

In: eLife, Vol. 7, e35447, 09.2018.

Research output: Contribution to journalArticle

Wang, Zheng ; Wu, Catherine ; Aslanian, Aaron ; Yates, John R. ; Hunter, Tony. / Defective RNA polymerase III is negatively regulated by the SUMO-ubiquitin-Cdc48 pathway. In: eLife. 2018 ; Vol. 7.
@article{b8c86fbdafb54ab5a4e17dd89110d94b,
title = "Defective RNA polymerase III is negatively regulated by the SUMO-ubiquitin-Cdc48 pathway",
abstract = "Transcription by RNA polymerase III (Pol III) is an essential cellular process, and mutations in Pol III can cause neurodegenerative disease in humans. However, in contrast to Pol II transcription, which has been extensively studied, the knowledge of how Pol III is regulated is very limited. We report here that in budding yeast, Saccharomyces cerevisiae, Pol III is negatively regulated by the Small Ubiquitin-like MOdifier (SUMO), an essential post-translational modification pathway. Besides sumoylation, Pol III is also targeted by ubiquitylation and the Cdc48/p97 segregase; these three processes likely act in a sequential manner and eventually lead to proteasomal degradation of Pol III subunits, thereby repressing Pol III transcription. This study not only uncovered a regulatory mechanism for Pol III, but also suggests that the SUMO and ubiquitin modification pathways and the Cdc48/p97 segregase can be potential therapeutic targets for Pol III-related human diseases.",
author = "Zheng Wang and Catherine Wu and Aaron Aslanian and Yates, {John R.} and Tony Hunter",
year = "2018",
month = "9",
doi = "10.7554/eLife.35447",
language = "English (US)",
volume = "7",
journal = "eLife",
issn = "2050-084X",
publisher = "eLife Sciences Publications",

}

TY - JOUR

T1 - Defective RNA polymerase III is negatively regulated by the SUMO-ubiquitin-Cdc48 pathway

AU - Wang, Zheng

AU - Wu, Catherine

AU - Aslanian, Aaron

AU - Yates, John R.

AU - Hunter, Tony

PY - 2018/9

Y1 - 2018/9

N2 - Transcription by RNA polymerase III (Pol III) is an essential cellular process, and mutations in Pol III can cause neurodegenerative disease in humans. However, in contrast to Pol II transcription, which has been extensively studied, the knowledge of how Pol III is regulated is very limited. We report here that in budding yeast, Saccharomyces cerevisiae, Pol III is negatively regulated by the Small Ubiquitin-like MOdifier (SUMO), an essential post-translational modification pathway. Besides sumoylation, Pol III is also targeted by ubiquitylation and the Cdc48/p97 segregase; these three processes likely act in a sequential manner and eventually lead to proteasomal degradation of Pol III subunits, thereby repressing Pol III transcription. This study not only uncovered a regulatory mechanism for Pol III, but also suggests that the SUMO and ubiquitin modification pathways and the Cdc48/p97 segregase can be potential therapeutic targets for Pol III-related human diseases.

AB - Transcription by RNA polymerase III (Pol III) is an essential cellular process, and mutations in Pol III can cause neurodegenerative disease in humans. However, in contrast to Pol II transcription, which has been extensively studied, the knowledge of how Pol III is regulated is very limited. We report here that in budding yeast, Saccharomyces cerevisiae, Pol III is negatively regulated by the Small Ubiquitin-like MOdifier (SUMO), an essential post-translational modification pathway. Besides sumoylation, Pol III is also targeted by ubiquitylation and the Cdc48/p97 segregase; these three processes likely act in a sequential manner and eventually lead to proteasomal degradation of Pol III subunits, thereby repressing Pol III transcription. This study not only uncovered a regulatory mechanism for Pol III, but also suggests that the SUMO and ubiquitin modification pathways and the Cdc48/p97 segregase can be potential therapeutic targets for Pol III-related human diseases.

UR - http://www.scopus.com/inward/record.url?scp=85055337743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055337743&partnerID=8YFLogxK

U2 - 10.7554/eLife.35447

DO - 10.7554/eLife.35447

M3 - Article

C2 - 30192228

AN - SCOPUS:85055337743

VL - 7

JO - eLife

JF - eLife

SN - 2050-084X

M1 - e35447

ER -